Experience with daptomycin in a tertiary pediatric hospital
BACKGROUND: Vancomycin has been considered the treatment of choice especially for methicillin-resistant Staphylococcus aureus (MRSA) infections; but its poor tissue penetration, renal toxicity, and requiring of dosages monitoring, raises the need for new treatment alternatives such as daptomycin.
AIMS: To analyze the safety and effectiveness of daptomycin in children.
METHODS: Children with microbiologically documented infections treated with daptomycin were retrospectively included.
RESULTS: The most frequent infections were endocarditis in 9 (32%), sepsis in 4 (14%), bacteremia in 7 (associated with catheter in 3) (25%), osteomyelitis in 3 (10%), peritonitis associated with dialysis in 3 (10%) and suppurative thrombophlebitis in 2 patients (p) (7%). Methicillin-resistant Staphylococcus aureus was the most common pathogen in 18 patients (64%). The indications for daptomycin were due to the failure of conventional treatment in 17 (61%), and the toxicity or intolerance to vancomycin in 11 patients (39%). The average duration of treatment was 19 days (95% ICR 7-42 days). Four patients (14%) completed outpatient treatment, 22 patients had a favorable response (79%). Adverse events were reported in 3 patients (2 creatinine-phosfo-kinase increase) and in one severe skin rash.
CONCLUSIONS: Daptomycin demonstrated a favorable efficacy and safety in this pediatric population.
| Errataetall: |
CommentIn: Rev Chilena Infectol. 2020 Aug;37(4):477-478. - PMID 33399670 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia - 37(2020), 1 vom: 31. Feb., Seite 19-22 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Experiencia con el uso de daptomicina en un hospital pediátrico de alta complejidad |
|---|
| Beteiligte Personen: |
Rosanova, María T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.08.2020 Date Revised 19.02.2021 published: Print CommentIn: Rev Chilena Infectol. 2020 Aug;37(4):477-478. - PMID 33399670 Citation Status MEDLINE |
|---|
| doi: |
10.4067/S0716-10182020000100019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313059519 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313059519 | ||
| 003 | DE-627 | ||
| 005 | 20231225145744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.4067/S0716-10182020000100019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313059519 | ||
| 035 | |a (NLM)32730395 | ||
| 035 | |a (PII)S0716-10182020000100019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Rosanova, María T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experience with daptomycin in a tertiary pediatric hospital |
| 246 | 3 | 3 | |a Experiencia con el uso de daptomicina en un hospital pediátrico de alta complejidad |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2020 | ||
| 500 | |a Date Revised 19.02.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Rev Chilena Infectol. 2020 Aug;37(4):477-478. - PMID 33399670 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Vancomycin has been considered the treatment of choice especially for methicillin-resistant Staphylococcus aureus (MRSA) infections; but its poor tissue penetration, renal toxicity, and requiring of dosages monitoring, raises the need for new treatment alternatives such as daptomycin | ||
| 520 | |a AIMS: To analyze the safety and effectiveness of daptomycin in children | ||
| 520 | |a METHODS: Children with microbiologically documented infections treated with daptomycin were retrospectively included | ||
| 520 | |a RESULTS: The most frequent infections were endocarditis in 9 (32%), sepsis in 4 (14%), bacteremia in 7 (associated with catheter in 3) (25%), osteomyelitis in 3 (10%), peritonitis associated with dialysis in 3 (10%) and suppurative thrombophlebitis in 2 patients (p) (7%). Methicillin-resistant Staphylococcus aureus was the most common pathogen in 18 patients (64%). The indications for daptomycin were due to the failure of conventional treatment in 17 (61%), and the toxicity or intolerance to vancomycin in 11 patients (39%). The average duration of treatment was 19 days (95% ICR 7-42 days). Four patients (14%) completed outpatient treatment, 22 patients had a favorable response (79%). Adverse events were reported in 3 patients (2 creatinine-phosfo-kinase increase) and in one severe skin rash | ||
| 520 | |a CONCLUSIONS: Daptomycin demonstrated a favorable efficacy and safety in this pediatric population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Daptomycin |2 NLM | |
| 650 | 7 | |a NWQ5N31VKK |2 NLM | |
| 700 | 1 | |a Sberna, Norma |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkis, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Ruvinsky, Silvina |e verfasserin |4 aut | |
| 700 | 1 | |a Berberian, Griselda |e verfasserin |4 aut | |
| 700 | 1 | |a Bologna, Rosa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia |d 1997 |g 37(2020), 1 vom: 31. Feb., Seite 19-22 |w (DE-627)NLM092581005 |x 0717-6341 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:1 |g day:31 |g month:02 |g pages:19-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4067/S0716-10182020000100019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 1 |b 31 |c 02 |h 19-22 | ||